中国伤残医学
中國傷殘醫學
중국상잔의학
CHINESE JOURNAL OF TRAUMA AND DISABILITY MEDICINE
2013年
9期
44-46
,共3页
多发性骨髓瘤( MM)%沙利度胺%VAD方案%不良反应%临床疗效
多髮性骨髓瘤( MM)%沙利度胺%VAD方案%不良反應%臨床療效
다발성골수류( MM)%사리도알%VAD방안%불량반응%림상료효
Multiple myeloma%Thalidomide%VAD regimen%Adverse reactions%Clinical efficacy
目的：对应用沙利度胺联合VAD方案治疗多发性骨髓瘤（ MM）的临床疗效及不良反应进行评价。方法：将42例初诊为MM患者，采用随机数字表法分为2组行对比治疗，其中，对照组采用VAD方案，治疗组在对照组VAD化疗方案的基础上联合沙利度胺，沙利度胺起始剂量100mg．d-1，分早晚口服，每周递增50mg，最大剂量300mg．d-1。2组均治疗3个疗程。结果：经过3个疗程的治疗后，治疗组22例患者，部分缓解12例，总有效率77．3％；对照组20例，部分缓解4例，总有效率55．0％，2组有效率比较差异有显著性（ P＜0．05）；在M-蛋白、骨髓浆细胞数及β2-微球蛋白等各项指标方面，2组与治疗前比较均有明显下降，而血红蛋白有显著上升，治疗组更为明显，差异有统计学意义（ P＜0．05）；治疗后各项指标组间比较差异有显著性（P＜0．05）。结论：较单用VAD方案，沙利度胺联合VAD方案在治疗多发性骨髓瘤的临床疗效上更为显著，且具有副作用少、耐受性好等优点，值得临床推广应用。
目的：對應用沙利度胺聯閤VAD方案治療多髮性骨髓瘤（ MM）的臨床療效及不良反應進行評價。方法：將42例初診為MM患者，採用隨機數字錶法分為2組行對比治療，其中，對照組採用VAD方案，治療組在對照組VAD化療方案的基礎上聯閤沙利度胺，沙利度胺起始劑量100mg．d-1，分早晚口服，每週遞增50mg，最大劑量300mg．d-1。2組均治療3箇療程。結果：經過3箇療程的治療後，治療組22例患者，部分緩解12例，總有效率77．3％；對照組20例，部分緩解4例，總有效率55．0％，2組有效率比較差異有顯著性（ P＜0．05）；在M-蛋白、骨髓漿細胞數及β2-微毬蛋白等各項指標方麵，2組與治療前比較均有明顯下降，而血紅蛋白有顯著上升，治療組更為明顯，差異有統計學意義（ P＜0．05）；治療後各項指標組間比較差異有顯著性（P＜0．05）。結論：較單用VAD方案，沙利度胺聯閤VAD方案在治療多髮性骨髓瘤的臨床療效上更為顯著，且具有副作用少、耐受性好等優點，值得臨床推廣應用。
목적：대응용사리도알연합VAD방안치료다발성골수류（ MM）적림상료효급불량반응진행평개。방법：장42례초진위MM환자，채용수궤수자표법분위2조행대비치료，기중，대조조채용VAD방안，치료조재대조조VAD화료방안적기출상연합사리도알，사리도알기시제량100mg．d-1，분조만구복，매주체증50mg，최대제량300mg．d-1。2조균치료3개료정。결과：경과3개료정적치료후，치료조22례환자，부분완해12례，총유효솔77．3％；대조조20례，부분완해4례，총유효솔55．0％，2조유효솔비교차이유현저성（ P＜0．05）；재M-단백、골수장세포수급β2-미구단백등각항지표방면，2조여치료전비교균유명현하강，이혈홍단백유현저상승，치료조경위명현，차이유통계학의의（ P＜0．05）；치료후각항지표조간비교차이유현저성（P＜0．05）。결론：교단용VAD방안，사리도알연합VAD방안재치료다발성골수류적림상료효상경위현저，차구유부작용소、내수성호등우점，치득림상추엄응용。
Objective:Thalidomide combined with VAD regimen of multiple myeloma ( MM) clinical efficacy and adverse reactions were evaluated .Methods 42 patients with newly diagnosed MM patients , using a random number table is divided into two sets of line com-pared treatment , The control group VAD regimen , thalidomide in the treatment group on the VAD regimen the basis of the control group , Starting dose of thalidomide 100mg.d-1, divided into morning and evening oral , Weekly increments 50mg, maximum dose 300mg.d-1.Two groups patients were treated for three course of treatment .Results:The treatment group of 22 patients, partial remission in 12 ca-ses, The total efficiency of 77.3%;The control group of 20 patients, partial remission in 4 cases, The total efficiency of 55%, Effective rates in the two groups had significant difference (P<0.05);IntheM-protein,bonemarrow plasma cells and β2-microglobulin(β2-MG) and other indicators , Two groups were significantly decreased compared with those before treatment , treatment of various indexes of the difference between groups was significant (P<0.05).Conclusion:In contrast to the use of VAD regimen , thalidomide combined with VAD regimen in the treatment of multiple myeloma clinical curative effect is more obvious , Having few side effects ,tolerance is good wait for an advantage , it is worthy of clinical application .
